Quick Answer
Aclaris Therapeutics, Inc. reported Stockholders Equity of $103.08 million for fiscal year 2025.
Aclaris Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $103.08M | -33.7% |
| 2024 | $155.55M | -1.0% |
| 2023 | $157.18M | -20.5% |
| 2022 | $197.62M | +0.1% |
| 2021 | $197.34M | +424.1% |
| 2020 | $37.65M | -46.1% |
| 2019 | $69.91M | -67.5% |
| 2018 | $215.12M | -4.5% |
| 2017 | $225.26M | +32.9% |
| 2016 | $169.49M | +83.2% |
| 2015 | $92.52M | +545.8% |
| 2014 | -$20.75M | -126.5% |
| 2013 | -$9.16M | -318.4% |
| 2012 | -$2.19M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $120.10M | -7.7% | -8.8% |
| June 30, 2025 | $131.74M | -1.6% | -8.6% |
| March 31, 2025 | $144.07M | +1.4% | -7.4% |
| December 31, 2024 | $155.55M | -1.0% | +19.5% |
| September 30, 2024 | $130.15M | -16.7% | -2.7% |
| June 30, 2024 | $133.82M | -25.6% | -5.8% |
| March 31, 2024 | $142.01M | -19.7% | -9.6% |
| December 31, 2023 | $157.18M | -20.5% | +0.5% |
- Aclaris Therapeutics, Inc. showed a decrease of -33.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Aclaris Therapeutics, Inc.’s stockholders equity has grown by 4806.9% (from -$2.19 million to $103.08 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: